CFM
VOR icon

Catalyst Funds Management’s Vor Biopharma VOR Stock Holding History

Catalyst Funds Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-538
Closed -$7.72K – 707
2025
Q1 		$7.72K Buy
+538
New +$12.9K ﹤0.01% 448
2024
Q4 		– Sell
-490
Closed -$6.86K – 1254
2024
Q3 		$6.86K Hold
490
– – ﹤0.01% 1224
2024
Q2 		$9.8K Buy
+490
New +$15.8K ﹤0.01% 928

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Catalyst Funds Management's VOR Position: Q2 2025 in Review

Catalyst Funds Management sold out of Vor Biopharma (VOR) in Q2 2025, closing a stake of 538 shares — an estimated $7.72K sold.

Catalyst Funds Management first reported a position in VOR in Q2 2024 and held it in 3 quarters. The position peaked at $9.8K in Q2 2024. 35 funds tracked by Wall St. Rank hold VOR as of Q2 2025.

  • Catalyst Funds Management reported no remaining Vor Biopharma position as of Q2 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 538 Vor Biopharma shares in Q2 2025, an estimated $7.72K.
  • Catalyst Funds Management first reported a position in Vor Biopharma in Q2 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Vor Biopharma position peaked at $9.8K in Q2 2024.
  • 35 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2025.

Based on Catalyst Funds Management's 13F filing for Q2 2025, filed 12 Aug 2025.